Business Context and Reporting Period
Indaptus Therapeutics, Inc. (INDP) filed a Current Report on Form 8-K on June 17, 2026, reporting the entry into a Material Definitive Agreement. The company is a Delaware corporation with principal executive offices in New York, New York, and its common stock trades on the Nasdaq Capital Market.
Key Financial Metrics and Transaction Details
- Transaction Type: Private Placement of Common Stock.
- Shares Issued: 20,000,000 shares.
- Purchase Price: $0.60 per share.
- Gross Proceeds: Approximately $12,000,000 (before offering expenses).
- Dilution: The issued shares represented less than 20% of the outstanding common stock prior to the transaction.
- Commissions: None paid; the placement was conducted directly by the company.
Material Changes and Agreements
The primary material change is the execution of a Stock Purchase Agreement with certain non-U.S. accredited investors. The transaction closed on June 17, 2026. Under the agreement, the Company is obligated to file a registration statement with the SEC within 90 days of closing to cover the resale of the shares and to use best efforts to have it declared effective within 75 days of filing. The Company will bear all fees and expenses related to this registration.
Outlook, Risks, and Unusual Items
The filing does not provide specific forward-looking guidance, management commentary on future operations, or a discussion of general business risks beyond the standard representations in the Purchase Agreement. The transaction was conducted in reliance on exemptions under Section 4(a)(2) of the Securities Act and Regulation S, involving offshore transactions with non-U.S. persons. No directed selling efforts were made in the United States.
Investor Verification Checklist
- Verify the exact number of shares outstanding prior to the June 17, 2026 closing to confirm the dilution impact.
- Review the specific offering expenses to be deducted from the $12,000,000 gross proceeds to determine net cash inflow.
- Monitor the filing of the registration statement for resale of shares, due within 90 days of June 17, 2026.
- Confirm the identity of the non-U.S. accredited investors if disclosed in subsequent filings or press releases.